Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data
In patients with T2DM, the use of DPP-4 inhibitors was associated with a significantly lower risk of developing pulmonary TB compared to non-use. Additionally, a longer cumulative duration of DPP-4 inhibitor may further reduce the TB risk.
Authors
- Chih‐Cheng Hsu (ORCID: https://orcid.org/0000-0003-4563-4341)
- Fu‐Shun Yen (ORCID: https://orcid.org/0000-0002-4677-2415)
- Chii‐Min Hwu (ORCID: https://orcid.org/0000-0002-8209-9627)
- Fuu‐Jen Tsai (ORCID: https://orcid.org/0000-0002-1373-245X)
- Teng‐Shun Yu (ORCID: https://orcid.org/0000-0002-8300-7157)
- Chen-Yü Sung
- Yang Chen (ORCID: https://orcid.org/0000-0001-7661-5923)
- Yu-Han Huang
Institutions
- Asia University (TW)
- National Yang Ming Chiao Tung University (TW)
- National Health Research Institutes (TW)
- China Medical University (TW)
- Min Sheng General Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Formosa University (TW)
- Chung Shan Medical University Hospital (TW)
- China Medical University Hospital (TW)
- Taipei Medical University (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- BMC Medicine
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1186/s12916-025-04423-1
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Clinical Trial Center, China Medical University Hospital
- China Medical University Hospital
- China Medical University
- Taipei Veterans General Hospital
- National Science and Technology Council
- Division of Materials Research